ANDA 208895, held by Sandoz. Carbidopa;Levodopa.
As of Nov 21, 2026, ANDA 208895 (Carbidopa; Levodopa), held by Sandoz, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 31, 2023 | Original application | Tentative approval |
| Carbidopa; Levodopa23.75MG;95MG · capsule, extended release;oral | Carbidopa;Levodopa | None (tentative approval) |
| Carbidopa; Levodopa36.25MG;145MG · capsule, extended release;oral | Carbidopa;Levodopa | None (tentative approval) |
| Carbidopa; Levodopa48.75MG;195MG · capsule, extended release;oral | Carbidopa;Levodopa | None (tentative approval) |
| Carbidopa; Levodopa61.25MG;245MG · capsule, extended release;oral | Carbidopa;Levodopa | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters